-
Je něco špatně v tomto záznamu ?
Renal activity of Akt kinase in experimental Type 1 diabetes
J. Ždychová, J. Veselá, L. Kazdová, R. Komers
Jazyk angličtina Země Česko
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- Klíčová slova
- Akt kinase, Diabetic nephropathy, Insulin, Mammalian targetof rapmycin, mTOR,
- MeSH
- diabetes mellitus 1. typu enzymologie farmakoterapie komplikace MeSH
- diabetické nefropatie enzymologie etiologie farmakoterapie MeSH
- experimentální diabetes mellitus enzymologie farmakoterapie komplikace MeSH
- financování organizované MeSH
- fosforylace MeSH
- hypoglykemika terapeutické užití MeSH
- inzulin krev terapeutické užití MeSH
- kinasa 3 glykogensynthasy metabolismus MeSH
- krevní glukóza metabolismus MeSH
- krysa rodu rattus MeSH
- kůra ledviny enzymologie účinky léků MeSH
- proteinkinasy metabolismus MeSH
- protoonkogenní proteiny c-akt metabolismus MeSH
- signální transdukce MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
Akt kinase regulates numerous cell functions including glucose metabolism, cell growth, survival, protein synthesis, and control of local hemodynamics. mTOR is one of down-stream effectors of Akt involved in the initiation of protein translation. However, renal Akt signaling in Type 1 diabetes (DM) in vivo, in particular under the conditions reflecting differences in metabolic control, has received less attention. Renal cortical activity and expression of Akt and mTOR (kinase assay, western blotting) were determined in streptozotocin-diabetic rats (D) with different levels of glycemic control (blood glucose 22.0±1.0, 13.4±1.5, 8.1±0.4 mmol/l, p<0.05 between the groups), achieved by varying insulin treatment (0, 4 and 12 IU/day), and in control rats with (C4) or without (C) chronic insulin administration. Renal Akt activity was reduced in D rats without insulin treatment and severe hyperglycemia (D-0, -62 %, p<0.01 vs. C), partially restored in moderately hyperglycemic rats (D-4, -30 %, p<0.05 vs. C), and normalized in D rats with intensive insulin and tight metabolic control (D-12). Expression of active mTOR paralleled Akt activity in D-0 (-51 %, p<0.01 vs. C), but not in D-4 and D- 12 that demonstrated increases in active mTOR (+55 %, +80 % resp., p<0.05) as compared to C. Moreover, insulin activated renal Akt (+82 %, p<0.01), but not mTOR in C4. In conclusion, glycemic control and intensity of insulin treatment are important modulators of renal Akt and mTOR activity in diabetes. While Akt activity is reversible by tight metabolic control, combination of hyperglycemia and insulin treatment resulted in enhancement of mTOR activity. In addition to Akt, other signaling pathways likely contribute to regulation of renal mTOR activity in diabetes.
Citace poskytuje Crossref.org
Lit.: 20
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10015693
- 003
- CZ-PrNML
- 005
- 20111210180546.0
- 008
- 100726s2008 xr e eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.931337 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Ždychová, Jana $7 xx0128624
- 245 10
- $a Renal activity of Akt kinase in experimental Type 1 diabetes / $c J. Ždychová, J. Veselá, L. Kazdová, R. Komers
- 314 __
- $a Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 504 __
- $a Lit.: 20
- 520 9_
- $a Akt kinase regulates numerous cell functions including glucose metabolism, cell growth, survival, protein synthesis, and control of local hemodynamics. mTOR is one of down-stream effectors of Akt involved in the initiation of protein translation. However, renal Akt signaling in Type 1 diabetes (DM) in vivo, in particular under the conditions reflecting differences in metabolic control, has received less attention. Renal cortical activity and expression of Akt and mTOR (kinase assay, western blotting) were determined in streptozotocin-diabetic rats (D) with different levels of glycemic control (blood glucose 22.0±1.0, 13.4±1.5, 8.1±0.4 mmol/l, p<0.05 between the groups), achieved by varying insulin treatment (0, 4 and 12 IU/day), and in control rats with (C4) or without (C) chronic insulin administration. Renal Akt activity was reduced in D rats without insulin treatment and severe hyperglycemia (D-0, -62 %, p<0.01 vs. C), partially restored in moderately hyperglycemic rats (D-4, -30 %, p<0.05 vs. C), and normalized in D rats with intensive insulin and tight metabolic control (D-12). Expression of active mTOR paralleled Akt activity in D-0 (-51 %, p<0.01 vs. C), but not in D-4 and D- 12 that demonstrated increases in active mTOR (+55 %, +80 % resp., p<0.05) as compared to C. Moreover, insulin activated renal Akt (+82 %, p<0.01), but not mTOR in C4. In conclusion, glycemic control and intensity of insulin treatment are important modulators of renal Akt and mTOR activity in diabetes. While Akt activity is reversible by tight metabolic control, combination of hyperglycemia and insulin treatment resulted in enhancement of mTOR activity. In addition to Akt, other signaling pathways likely contribute to regulation of renal mTOR activity in diabetes.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a experimentální diabetes mellitus $x enzymologie $x farmakoterapie $x komplikace $7 D003921
- 650 _2
- $a diabetes mellitus 1. typu $x enzymologie $x farmakoterapie $x komplikace $7 D003922
- 650 _2
- $a diabetické nefropatie $x enzymologie $x etiologie $x farmakoterapie $7 D003928
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a kinasa 3 glykogensynthasy $x metabolismus $7 D038362
- 650 _2
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 _2
- $a inzulin $x krev $x terapeutické užití $7 D007328
- 650 _2
- $a kůra ledviny $x enzymologie $x účinky léků $7 D007672
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a proteinkinasy $x metabolismus $7 D011494
- 650 _2
- $a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a signální transdukce $7 D015398
- 653 00
- $a Akt kinase
- 653 00
- $a Diabetic nephropathy
- 653 00
- $a Insulin
- 653 00
- $a Mammalian targetof rapmycin
- 653 00
- $a mTOR
- 700 1_
- $a Veselá, J. $7 _AN051216
- 700 1_
- $a Kazdová, Ludmila, $d 1938- $7 xx0053119
- 700 1_
- $a Komers, Radko $7 xx0071643
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 57, č. 5 (2008), s. 709-715 $x 0862-8408
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/57/57_709.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 8
- 990 __
- $a 20100708110758 $b ABA008
- 991 __
- $a 20100810145609 $b ABA008
- 999 __
- $a ok $b bmc $g 756108 $s 619889
- BAS __
- $a 3
- BMC __
- $a 2008 $b 57 $c 5 $m Physiological research $x MED00003824 $d 709-715
- LZP __
- $a 2010-32/vtme